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Introduction
Approximately, 5–10% of cancer cases have a hereditary 
pattern, which is caused by germline mutations in oncogenes 
and tumor suppressor genes [1–5]. The presence of a family 
history of cancer is one of the most important risk factors 
for this type of neoplasia [6]. Thus, the identification of 
individuals at- risk is crucial for the application of proper 
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Abstract
One of the challenges for Latin American countries is to include in their health-
care systems technologies that can be applied to hereditary cancer detection 
and management. The aim of the study is to create and validate a questionnaire 
to identify individuals with possible risk for hereditary cancer predisposition 
syndromes (HCPS), using different strategies in a Cancer Prevention Service in 
Brazil. The primary screening questionnaire (PSQ) was developed to identify 
families at- risk for HCPS. The PSQ was validated using discrimination measures, 
and the reproducibility was estimated through kappa coefficient. Patients with 
at least one affirmative answer had the pedigree drawn using three alternative 
interview approaches: in- person, by telephone, or letter. Validation of these 
approaches was done. Kappa and intraclass correlation coefficients were used 
to analyze data’s reproducibility considering the presence of clinical criteria for 
HCPS. The PSQ was applied to a convenience sample of 20,000 women of 
which 3121 (15.6%) answered at least one affirmative question and 1938 had 
their pedigrees drawn. The PSQ showed sensitivity and specificity scores of 
94.4% and 75%, respectively, and a kappa of 0.64. The strategies for pedigree 
drawing had reproducibility coefficients of 0.976 and 0.850 for the telephone 
and letter approaches, respectively. Pedigree analysis allowed us to identify 465 
individuals (24.0%) fulfilling at least one clinical criterion for HCPS. The PSQ 
fulfills its function, allowing the identification of HCPS at- risk families. The 
use of alternative screening methods may reduce the number of excluded at- risk 
individuals/families who live in locations where oncogenetic services are not 
established.
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Open Access
3015© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Screening Hereditary Cancer SyndromesN. Campacci et al.
preventive and therapeutic measures [2, 7] and represents 
an enormous potential for cancer risk reduction. In addi-
tion, the accurate identification of relatives’ wild type for 
the mutation segregating in an at- risk family reassures the 
individual and eliminates the expenses and complications 
of unnecessary screening and preventive interventions.
One of the challenges for Latin American countries is 
to introduce hereditary cancer healthcare approaches, with 
new unexpensive technologies, including screening, genetic 
counseling, and genetic testing for early detection and diag-
nosis [8]. In Brazil, there are few specialized services for 
hereditary cancer predisposition syndromes (HCPS) diagnosis 
and follow- up [9]. These services are primarily available at 
hospitals attached to medical schools and expensive private 
institutions, mainly located in major population centers, 
restricting and prejudicing their access [8, 10]. Making mat-
ters worse, given the low literacy of a significant proportion 
of the Brazilian inhabitants [11], part of the general popula-
tion is unaware of the existence and importance of this 
type of service [12]. Additional reasons for lack of recogni-
tion and knowledge regarding hereditary cancer in Brazil 
include the absence of specialized human resources to meet 
such demand and the unawareness of the possibility of 
using family history for cancer prevention [13], despite 
substantial government programs and the evidence that 
family history can be used in primary care for disease control 
[14, 15]. As a consequence of all facts exposed above, the 
attention focused on the screening and identification of 
individuals and families at- risk for HCPS remains limited 
in Brazil and other Latin American countries [16, 17].
Developed countries also face difficulties related to the 
identification of HCPS families, due to the increasing 
demand of patients and families at- risk for hereditary 
cancer identified and consequent lack of infrastructure 
and personnel to meet this growing necessity [18–21]. 
This problem will inevitably occur in developing countries 
such as Brazil as soon as oncogenetics services become 
available to the entire population. There is a worldwide 
need for more cost- effective strategies to expand the acces-
sibility of Cancer Genetics services without overburdening 
health services and healthcare professionals [22, 23].
Accordingly, the aim of this study was to create and 
validate a simple instrument for the identification of fami-
lies at- risk for hereditary breast, ovarian, and/or colorectal 
cancer, as well as to validate different strategies for pedigree 
drawing of those at- risk individuals identified.
Methods
The primary screening questionnaire
The primary screening questionnaire (PSQ) intents to be 
an easy and quick way to identify individuals and/or families 
probably at- risk for HCPS, mainly focusing on breast, ovar-
ian, and/or colorectal cancer predisposition syndromes.
The PSQ contains information regarding the age of 
cancer diagnosis and number of tumors in the family, 
which are the basis of most clinical criteria, such as ASCO 
[24, 25], NCCN [26], and Amsterdam [27]. In addition, 
because breast and colorectal cancers are present in a 
higher frequency in our population, a specific question 
addressing these two tumor types were also included.
The questionnaire was structured to have a YES/NO answer 
for the following questions: Q1—Personal history of cancer 
before the age of 50 years; Q2A—First- or second- degree 
relatives with breast cancer (BC) before the age of 50; Q2B—
First- or second- degree relatives with ovarian cancer (OC); 
Q2C—First- or second- degree relatives with colorectal cancer 
(CRC) before the age of 50; and Q3—Three or more first-
 or second- degree relatives with cancer.
Population of the study
The PSQ was applied in a convenience sample of 20,000 
women from Barretos Cancer Hospital (BCH) during a 
period of 12 months. Women submitted to a routine 
mammogram or cervical cancer screening were invited to 
participate in the study regardless of her personal or fam-
ily cancer history.
The Cancer Prevention Unit at BCH (Barretos, Brazil) 
performs population- based preventive cancer screening and 
attends more than 100,000 individuals per year. The Institution 
also has 12 Mobile Units, which perform prevention screen-
ing regarding breast, cervix, prostate, and skin cancer all 
over the Brazilian territory, reaching remote areas [28–30]. 
For the purpose of the present study, women performing 
mammogram or cervical cancer screening at the Cancer 
Prevention Unit at BCH or, also, in the Mobile Units that 
cover São Paulo state, were invited to participate.
Secondary screening
All women who answered affirmatively to at least one of 
the PSQ questions were invited to participate in a second 
phase of the study. This secondary screening involved a 
further analysis of the family cancer history with pedigree 
drawing (including at least three generations), encompass-
ing maternal and paternal family history. A properly trained 
healthcare professional (nurse with experience in Cancer 
Genetics) conducted the second phase, using three dif-
ferent approaches, as described below.
In- person approach
After informed consent fulfilling, the appointment consisted 
of an initial conversation to provide a general explanation 
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about the importance of cancer prevention and early 
detection. At this moment, educational materials regarding 
cancer prevention and genetic risk factors associated with 
cancer development were provided to the participant [12]. 
Next, the pedigree was drawn. The language used through-
out the process was simple and easily comprehensible for 
all patients independent of the education/literacy level.
Telephone approach
In this approach, the pedigree was created from informa-
tion obtained by telephone and by the same interviewer 
who conducted the in- person interviews. Telephone con-
versations lasted 30–40 min. Once again, the language 
was simple and easily comprehensible for participants with 
different education levels. After hearing the informed 
consent (by telephone), the participant could decline to 
participate in the study and end the telephone call if 
desired.
This approach was performed for those women report-
ing unavailability to visit the health service, due either 
to work or domestic activities.
Letter approach
In this approach, an envelope with the following items 
was mailed to the participants: (1) a letter that explained 
the research project and what procedures were involved 
in the second phase of the study; (2) two copies of the 
informed consent; (3) a questionnaire with several ques-
tions regarding the family history of cancer in the first- , 
second- , and third- degree relatives, including the type of 
cancer, age at diagnosis, current age or age at death, the 
presence of multiple or bilateral tumors, and the relation-
ship of the cancer patient to the person who was filling 
out the questionnaire (the questionnaire was adapted from 
a model of the Brazilian Network of Familial Cancer); 
and (4) a stamped envelope, so the participant could 
return the questionnaire and the informed consent, free 
of charge, by mail.
The letter approach was used for those women who 
could not be reached by telephone (had no telephone 
number or did not answer the telephone).
Primary screening questionnaire validation
The sensitivity, specificity, positive, and negative predictive 
values of the PSQ were evaluated using the kappa 
coefficient.
To calculate the sample size needed for this validation, 
the presence of a positive family history of cancer was 
considered. In the case of a positive PSQ, where the 
expected ratio is 0.80, with a significance of 0.05, absolute 
error of 0.09 in the confidence interval, and the popula-
tion size of 1938 (number of women who answered posi-
tively in our study and had the pedigree drawn), the 
validation would require about 69 cases. In the same way, 
it was possible to identify the proportion of no family 
history of cancer for those who answered “NO” in the 
PSQ. Thus, for the negative group of the PSQ (popula-
tion size of 16,879 women), taking into account the 
expected ratio of 0.80, a significance of 0.05, absolute 
error 0.075, and population size in the confidence interval, 
107 cases would be necessary.
Based on these estimates, a sample of 69 women with 
at least one affirmative answer to the PSQ and 107 women 
with negative responses to all PSQ questions were rand-
omized. Pedigrees were drawn for all 176 cases. In addi-
tion, the PSQ was reapplied 6 months after the first 
application. At each stage, the questionnaires were applied 
independently, meaning that the interviewers did not know 
the answers of previous applications.
Validation of pedigree drawing
The sample size for validation of the approaches (in per-
son, by telephone, and letter) was estimated based on 
the reproducibility of clinical criteria using the table pub-
lished by Sim & Wright [31]. An expected kappa of 0.8, 
alpha of 0.05, and a power of 0.9 with a kappa coefficient 
under the null hypothesis of 0.4 were considered. 
Additionally, considering that the proportion of positive 
cases of HCPS at the study population was of 0.3, around 
60 cases were needed. The in- person approach was con-
sidered as the gold standard strategy. To validate the tel-
ephone approach, 60 cases in which the pedigree was 
created from information obtained “in- person” were ran-
domly selected. Then, telephone calls were made to these 
subjects. These confirmation calls were not performed by 
the same person who performed the in- person interview, 
and the callers had no access at the time of the interview 
or earlier to the previously created pedigrees.
The validation was also performed for the letter approach. 
A total of 60 cases whose pedigree was initially created 
from information obtained by letter were analyzed and 
systematically compared with the telephone approach once 
this approach was validated.
To verify the reproducibility of the approaches, kappa 
(for categorical variables) and intraclass correlation coef-
ficients (for numerical variables) were calculated, by com-
paring the following variables: fulfillment of HCPS clinical 
criteria (yes/no, and if yes, which criteria), number of 
generations, number of generations affected by cancer, 
total number of tumors, number of first- and second- 
degree relatives with cancer, and those with cancer before 
the age of 50.
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Regarding fulfilling HCPS criteria, the clinical criteria 
for the main hereditary breast and/or colorectal cancer 
predisposition syndromes, such as hereditary breast ovar-
ian cancer (HBOC) [26], Li–Fraumeni syndrome (LFS) 
[32], hereditary breast and colorectal cancer (HBCC) [24, 
25], familial adenomatous polyposis—FAP [3] (considering 
the presence of personal or family history of polyps or 
previous polypectomy), and Lynch Syndrome [27], were 
considered.
Referral for specialized Cancer Genetics 
service
All families that fulfilled at least one clinical criterion for 
any HCPS are being referred to the Oncogenetics 
Department of BCH, and, after genetic counseling and 
family history confirmation, they are referred to the Center 
of Molecular Diagnosis of the same Institution for genetic 
testing, if warranted [9].
Ethical aspects
All the participants completed the informed consent. The 
study was approved by the Research Ethics Committee 
of the BCH, Sao Paulo state, Brazil, under protocol num-
ber 413/2010.
Results
The primary screening questionnaire
From the total sample of 20,000 women enrolled, 17,092 
were from the Mobile Units and 2909 from the Hospital 
Unit. They were from 381 cities distributed along 20 dif-
ferent Brazilian states. The average age was 51 years 
(SD = 9.45), ranging from 18 to 79 years of age. As it 
would be expected, since the participants were women 
performing regular mammogram and/or cervical cancer 
screening, the great majority of the participants (91.0%) 
were older than 40 years.
From all of them, 3121 (15.6%) answered affirmatively 
to at least one PSQ question. The most frequent positive 
answer was regarding the presence of first- or second- 
degree relatives with BC before the age of 50 (n = 1438, 
46.0% of the respondents). Detailed information, question 
by question, can be found in Table 1.
Secondary screening
Among the 20,000 women who completed the PSQ, 3121 
(15.6%) had at least one positive answer and were invited 
to the second phase of the study. During the second part 
of the screening, there was an attempted to approach each 
of the 3121 women in order to draw their pedigree. Of all 
the participants (3121), 17 were unable to participate in the 
study (6 died and 11 had psychological problems and their 
relatives did not want to respond), 79 directly verbalized 
that they did not want to participate, and a total of 1087 
were unsuccessfully attempted to be contacted by telephone 
or letter. In order to eliminate the possibility of bias due 
to the number of participants that were unable to be con-
tacted, chi- square test was realized to compare the profile 
of answers in PSQ in the group that was possible to reach 
and had the pedigree analysis with the group that was unable 
to be contacted. The result of this analysis shows that the 
profile of affirmative responses is similar, reducing the pos-
sibility that we have recruited only those of higher risk or 
those of lower risk.
In total, 1938 women (62.1% of the total sample) were 
reached, and the pedigree for each of them was drawn. 
Using the “in- person” approach, we were able to reach 
and draw 220 (11.3%) pedigrees, while 310 (16.0%) and 
1408 (72.6%) women were reached by letter and telephone, 
respectively. Figure 1 depicts the study phases with the 
number of participants enrolled in each phase.
We conducted a detailed analysis of all 1938 obtained 
pedigrees. The number of cancer- affected probands was 
200 (10.3%) excluding skin nonmelanoma cases, and the 
most frequent type of cancer was breast (66 cases, 33.0%), 
cervix/uterus (47 cases, 23.5%), and thyroid cancer (20 
cases, 10.0%). The families evaluated showed a large num-
ber of relatives, ranging from 2 to 30 relatives of first 
degree and 4–27 of second degree. The mean number of 
tumors was two per family (SD = 1.67; 95% CI: 0–13). 
Considering the tumor spectrum present in those families, 
some interesting findings are depicted in Table 2. Ninety- 
nine families with BC cases before the age of 35 were 
identified, and among them, six families had more than 
one of those cases in their families.
Regarding clinical criterion for HCPS, the following 
guidelines were considered: ASCO [24], NCCN [26], 
Table 1. Number of positive answers for questions in PSQ. 
N %*
Q1—Personal history of cancer before 
the age of 50 years old;
554 17.7
Q2A—First- or second- degree relatives 
with BC before the age of 50;
1438 46.0
Q2B—First- or second- degree relatives 
with OC;
662 21.0
Q2C—First- or second- degree relatives 
with CRC before the age of 50;
456 14.6
Q3—Three or more first/second- degree 
relatives with cancer.
800 25.6
*One participant can answer affirmatively to more than one question in 
PSQ.
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Amsterdam [33], Bethesda [27], and Li–Fraumeni (classic 
proposed by Li and Fraumeni and, for Li Fraumeni like, 
those proposed by Birch and by Chompret) [32, 34]. In 
addition, the criteria proposed by the Brazilian Institute 
of Cancer (for polyposis) were also considered [3].
Among the 1938 families carefully analyzed, 465 (24.0%) 
had at least one clinical criterion; 402 (20.7%) cases had 
only one criterion present in the family; 57 (2.9%) fulfilled 
two different criteria in the family; and 6 (0.3%) had 
three criteria identified. The results obtained are consistent 
with the literature, where the less stringent criteria were 
the more frequently observed: 273 families fulfilling the 
NCCN criteria for HBOC syndrome [26] and 195 families 
with the Bethesda criteria for Lynch syndrome [27]. Table 3 
sets out the main clinical criteria observed.
Validations
Primary screening questionnaire
The PSQ validity was measured by the sensitivity, speci-
ficity, positive and negative predictive values, as well as 
through the calculation of kappa coefficient for the com-
parison with pedigree data (Fig. 2A). The sensitivity and 
specificity rates of the PSQ to identify families with clinical 
criteria for an HCPS were 94.4% (95% CI [0.813–0.993]) 
and 75% (95% CI [0.669–0.818]), respectively. The posi-
tive predictive value of the instrument was 49.3% (95% 
CI [0.419–0.566]), and the negative predictive value was 
98.1% (95% CI [0.931–0.995]), showing that the PSQ 
satisfies the real necessity for screening families at potential 
risk (Table S1 shows the rationale to calculate sensitivity, 
specificity, and positive predictive value and negative pre-
dictive value).
The reproducibility of the PSQ considering an interval 
of 6 months between application and reapplication was 
also evaluated. The kappa value obtained was 0.646 
(SD = 0.05, P < 0.001), presenting good concordance 
between both time points, pointing to the accuracy of 
self- reported personal and family history.
Approaches for obtaining cancer family history
Considering the difficulties we faced to have all partici-
pants coming to the Hospital Unit for the secondary 
screening phase, alternative strategies were employed to 
obtaining their pedigree. All strategies were validated con-
sidering, as detailed in the methodology, the “in person” 
Figure 1. Flowchart.
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strategy as the gold standard. Figure 2B demonstrates a 
flowchart that simplifies the process of validation.
Telephone approach validation
Considering the reproducibility among the variables in the 
two approaches analyzed: in- person and telephone (Table 4), 
the kappa coefficient was calculated and, considering the 
presence of clinical criteria for any HCPS, a highly repro-
ducible kappa value of 0.976 (error value of 0.023) was 
obtained. This outcome demonstrates that the completion 
of this questionnaire by telephone is feasible and reliable.
Letter approach validation
The validation of the letter approach was performed by 
telephone, depending on the availability of the 60 cases 
randomly selected for the validation. This analysis occurred 
after the telephone approach validation. This procedure 
was performed by three different professionals who had 
no access to the previously created pedigrees.
Table 4 shows the reproducibility values obtained for 
the different variables considered. Considering the pres-
ence of clinical criteria, a kappa value of 0.850 was obtained, 
which is considered a highly reproducible value [31].
Concordance of clinical criteria fulfillment, calculated 
from pedigrees constructed with the in person, tele-
phone, or letter, showed that all three approaches were 
reliable to identify individuals and/or families at- risk 
for HPCS.
Discussion and Conclusion
The PSQ had high sensitivity (94.4%) and specificity (75%), 
showing that it is an effective tool for identifying indi-
viduals and/or families at- risk for hereditary cancer in a 
population- based sample. In fact, taking into account that 
the PSQ was not strict and that HCPS are relatively rare, 
the NPV (98.1%) revealed that few families at- risk for 
hereditary cancer were missed. The PSQ reproducibility 
was good (kappa coefficient of 0.646), which is a char-
acteristic of a precise and consistent screening tool. It is 
possible that the kappa coefficient was not higher because 
family history is dynamic and can change along time.
Ashton- Prolla and colleagues previously developed and 
applied a questionnaire with seven questions related to 
breast, ovarian, and colorectal cancer family history in the 
South of Brazil [35]. The authors analyzed a total of 9218 
participants, of which 885 (9.6%) provided a positive 
response regarding a personal and/or family history of 
cancer. From those, 211 women (23.8%) exhibited a sug-
gestive family history of breast and colorectal predisposition 
syndromes. When comparing both methods, we detected 
two main differences: (1) The seven- question questionnaire 
Table 2. Frequency of the type of the tumor in the analyzed families.
Type of cancer General frequency General %
Number of cases in 
the same family Relative frequency Relative %
Breast cancer before 
35 years old
99/1938 5.1 1 93/99 93.9
2 6/99 6.1
Bilateral breast cancer 17/1938 0.9 1 17/17 100
2 – –
Male breast cancer 1/1938 0.05 1 1/1 100
2 – –
Colorectal cancer 
before 50 years old
195/1938 10.0 1 171/195 87.7
2 24/195 12.3
Pancreatic cancer 44/1938 2.3 1 44/44 100
2 – –
Ovarian cancer 39/1938 2.0 1 38/39 97.4
2 1/39 2.6
Table 3. Number of families per clinical criteria*
Clinical criteria N† %
HBOC (ASCO criteria) 37 2.0
HBOC (NCCN criteria) 273 14.1
Lynch syndrome (Amsterdam criteria) 13 0.7
Lynch syndrome (Bethesda criteria) 195 10.0
Li–Fraumeni like (Birch criteria) 11 0.6
Li–Fraumeni like (Chompret criteria) 8 0.4
Cowden syndrome (CCOD criteria) 19 1.0
Familial adenomatous polyposis (INCA criteria) 6 0.3
HBOC, hereditary breast and ovarian cancer; ASCO, American Society 
of Clinical Oncology; NCCN, National Comprehensive Cancer Network; 
CCOD, cowden consortium operational diagnoses; INCA, Brazilian 
National Cancer Institute—National Network of Familial Cancer, Brazil. 
*The percentage value was calculated considering the number of 
families per clinical criteria from a total of 1938 that had the pedigree 
drawn. 
†Some families could had more than one clinical criterion.
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developed by Ashton- Prolla is more HBOC/HBCC- directed 
than the PSQ described here, and (2) the questionnaires 
were administered in different Brazilian states with distinct 
populations and characteristics. However, the percentage 
of at- risk families identified was similar.
Regarding secondary screening data (pedigree analysis), 
the “presence of clinical criteria for HCPS” was chosen 
as the “comparison variable” for the analysis of informa-
tion reproducibility, because most of the evaluated variables 
(e.g., age at cancer diagnosis, number of generations and 
cancer cases in the family) belong to the clinical criteria 
for the majority of HCPS. Thus, considering the presence 
of clinical criteria (in the family) as reference, high repro-
ducibility for the telephone (0.976) and letter approaches 
(0.850) was obtained, which demonstrated that the most 
important aspects of the family history of cancer could 
be obtained through both strategies. Therefore, the reli-
ability of the obtained information [15] and the validity 
of these approaches for identifying families at- risk for 
hereditary cancer were demonstrated. Results obtained in 
this study may generate several healthcare benefits: (1) 
increase access to highly specialized services with Hereditary 
Cancer Genetics department, (2) reach a specific popula-
tion that is not able to go to the health services, (3) 
reduction of stress, costs, and time (required for travel 
to the first consultation), (4) promote efficient commu-
nication between health services and their users, and (5) 
train health system managers/governors aware of the 
importance of creating and maintaining this type of spe-
cialized service in Genetics and Cancer.
Several studies report the use of alternative methods 
for patient access [19, 36, 37]. Pieper et al. [19]. evaluated 
a questionnaire to screen individuals at- risk for hereditary 
CRC in a sample of private service users in Germany. A 
questionnaire on the presence of a family history of CRC 
was mailed to 12,139 individuals. Of these, 2355 individu-
als completed and returned the questionnaire, and it was 
verified that 373 (16%) of the participants had some risk 
Figure 2. Validation approaches. (A) PSQ validation. (B) Telephone and letter validation.
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for hereditary CRC. A study developed by Joseph and 
colleagues [36] had a screening questionnaire that was 
applied by telephone, and, according to the answers, it 
was possible to score it and verify if the person was eligible 
for genetic counseling. Other authors [37], 4 years later, 
used the same methodology to screen by telephone indi-
viduals eligible for genetic counseling. The studies cited 
above identified high- risk families that could participate 
in different strategies of cancer risk assessment.
In addition to screening strategies, new alternatives have 
been used for the genetic counseling process. In a study 
by Platten et al., genetic counseling was performed by tel-
ephone to identify individuals at- risk and facilitate their 
assistance [23]. It was observed that the patient’s service 
satisfaction and feelings regarding the care provided by 
this type of approach had the same outcomes as observed 
in a conventional method. Another study published by 
Kinney and collaborators in 2016 compared genetic coun-
seling by telephone with the in- person strategy for individuals 
that live in geographically diverse areas and concluded that 
telephone counseling can be effectively used to increase 
access without long- term adverse psychosocial consequences 
[38].
An important issue to address is the importance of the 
educational strategies, once this is a general population 
that may have never listen about “Oncogenetics” or 
“Hereditary Cancer” [12]. Educational tools can be devel-
oped to help the process like, for example, a brochure 
that can be delivered during the prevention exams and 
can help on the understanding of the associated concepts 
and also contribute to reduce the stress concerning the 
first consultation on Genetics department.
We could, with the present study, identify that, among 
those who answered positively in the PSQ, 24% (465 women) 
had at least one clinical criterion for HCPS. Even though 
the prevalence of HCPS cannot be inferred from this study, 
the prevalence in a selected sample can still add important 
information for cancer programs planning. All at- risk iden-
tified cases are being referred to the Oncogenetics depart-
ment for cancer genetic counseling and, for those families 
with criteria for genetic testing, the same is performed 
without any charge to the patient. It is important to empha-
size that there is a very low probability that this group of 
women would have had the opportunity to have a con-
sultation with a geneticist outside the context of the present 
study, revealing the necessity of screening strategies in 
countries of lower socioeconomic level.
Regarding difficulties faced during the study, we can 
point out the problem to access the entire population. 
We had a loss of 38% in the sample group that answered 
at least one affirmative question in PSQ (3121). This can 
be justified by the fact that most of the participants were 
from remote areas (inner region of the country). In addi-
tion, the great majority is economically active, which makes 
harder the possibility of reaching health services.
This study has some limitations as the fact that, with 
few exceptions, the tumor diagnosis was not confirmed 
by death certificates or pathology reports. Besides, some-
times, the age at cancer diagnoses was not properly con-
sidered at the time of PSQ application. When comparing 
the PSQ answers with the pedigrees, we could see that 
if the participant had a previous diagnosis of cancer, she 
got a “YES” in the first PSQ question, regardless of age 
at diagnosis. The same is true for answers is questions 
Q2A to Q2C. Another limitation that should be addressed 
is the fact that some cases of OC may have been lost if 
they were diagnosed over the age of 50 in the study 
participants.
In conclusion, it is worth noting the importance of 
using alternative forms of patient access and identification 
Table 4. Kappa values for reproducibility of the telephone approach compared with the in- person approach and letter approach compared with the 
telephone approach.
Variable
Coefficient of reproducibility and concordance
Telephone approach Letter approach
Clinical criteria 0.976† (95% CI [0.930–1]) 0.850† (95% CI [0.709–0.991])
Number of generations 0.259† (95% CI [−0.235–0.556]) 0.641† (95% CI [0.217–1])
Number of affected generations 0.699† (95% CI [0.497–0.820]) 0.694† (95% CI [0.565–0.824])
Number of first- degree relatives 0.962† (95% CI [0.936–0.977]) 0.920† (95% CI [0.870–0.970])
Number of first- degree relatives with cancer 
before age 50
0.824† (95% CI [0.706–0.895]) 0.827† (95% CI [0.702–0.953])
Number of second- degree relatives 0.824† (95 CI [0.706–0.895]) 0.768† (95% CI [0.639–0.897])
Number of second- degree relatives with cancer 
before age 50
0.828† (95% CI [0.707–0.899]) 0.595† (95% CI [0.312–0.879])
Total number of tumors 0.806* (95% CI [0.673–0.884]) 0.861* (95% CI [0.776–0.915])
CI, confidence interval.
*Intraclass correlation coefficient: calculated because it was a numerical variable.
†Kappa.
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of families at- risk for hereditary cancer. Considering the 
extensive Brazilian geographic area, the scarcity of onco-
genetics services, and the concentration of these services 
in a few cities, Brazil (and other countries with the same 
reality), there is a need for different strategies to reduce 
disparities in healthcare access [39] and new strategies 
for cancer prevention. The current study demonstrates, 
in a simple way, the high quality of the information 
obtained through unconventional approaches for pedigree 
drawing. These approaches can be used to assemble a 
detailed and reliable family history and identify (even in 
geographically remote areas) families at- risk for hereditary 
cancer. The information obtained will be useful to refer 
such families to appropriate preventive programs accord-
ing to their risk, thus reducing the risk of cancer and 
increasing the possibility of a real personalized 
medicine.
Practice Implications
The process of screening individuals and families who 
may be at- risk could be more economical and faster, 
particularly where the healthcare delivery system remains 
underdeveloped and where problems occur in the organi-
zation and delivery of preventive practices.
The achievement of this simple questionnaire (PSQ) 
during screening tests can be highly effective since the 
patient is already present in the preventive care environ-
ment, not restricting only to populations that have already 
been diagnosed with cancer or those already considered 
of high risk.
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